# iwCLL 2018 guidelines and response criteria

Source: https://onco.cc/terms/iwcll-2018/  
OnCo record `iwcll-2018` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The iwCLL guidelines are the international rules for diagnosing chronic lymphocytic leukaemia, deciding when it needs treatment, and judging how well treatment has worked.

## Summary

The International Workshop on Chronic Lymphocytic Leukemia guidelines of 2008 were revised in 2018 (Hallek and colleagues, Blood) in light of the genomic landscape, prognostic genetic tests, minimal residual disease testing and new targeted drugs. The revision includes updated response criteria, the use of MRD status in clinical evaluation, and advice on viral infections. The same guidelines set the indications for starting treatment, which is why many people with CLL are watched without treatment.

## Fields

- Kind: Term
- Last checked: 2026-11-04
- Also known as: iwCLL; iwCLL 2018; iwCLL criteria; iwCLL guidelines; Hallek 2018

## Sources

- Hallek et al., iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL (Blood 2018): https://doi.org/10.1182/blood-2017-09-806398

## Connected records

- terms: [Complete response (CR) and partial response (PR)](https://onco.cc/terms/complete-response-term/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/), [Tsukasaki 2009 response criteria (adult T-cell leukaemia-lymphoma)](https://onco.cc/terms/tsukasaki-atl-response/), [Undetectable MRD (uMRD / MRD-negative)](https://onco.cc/terms/umrd/)
- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)

---
JSON: https://onco.cc/api/v1/entities/iwcll-2018.json